Fig. 2From: Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamideIllustrative example of BSI analysis and PSA change after treatment with enzalutamide at 12-week treatment follow-up. Lesions detected and classified as metastatic by the neural network of the automated EXINI platform for BSI calculation are highlighted in red Back to article page